Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-4ef629a7127d0f0a54242fe28701c54c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-4ef629a7127d0f0a54242fe28701c54c"/>
<resource>
<Composition>
<id value="composition-en-4ef629a7127d0f0a54242fe28701c54c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-4ef629a7127d0f0a54242fe28701c54c"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-4ef629a7127d0f0a54242fe28701c54c</b></p><a name="composition-en-4ef629a7127d0f0a54242fe28701c54c"> </a><a name="hccomposition-en-4ef629a7127d0f0a54242fe28701c54c"> </a><a name="composition-en-4ef629a7127d0f0a54242fe28701c54c-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1323/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - ilumetri</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1323/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp4ef629a7127d0f0a54242fe28701c54c"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - ilumetri"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Ilumetri is and what it is used for</li><li>What you need to know before you use Ilumetri</li><li>How to use Ilumetri</li><li>Possible side effects</li><li>How to store Ilumetri</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What ilumetri is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What ilumetri is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Ilumetri contains the active substance tildrakizumab. Tildrakizumab belongs to a group of medicines called interleukin (IL) inhibitors. This medicine works by blocking the activity of a protein called IL-23, a substance found in the body which is involved in normal inflammatory and immune responses and which is present at increased levels in diseases such as psoriasis.</p><p>Ilumetri is used to treat a skin condition called plaque psoriasis, in adults with moderate to severe disease.<br/>Using Ilumetri will benefit you by improvements of skin clearance and reducing your symptoms.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take ilumetri"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take ilumetri"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Ilumetri:</p><ul><li>If you are allergic to tildrakizumab or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have an infection which your doctor thinks is important, for example, active tuberculosis which is an infectious disease affecting mainly the lungs.</li></ul><p>Warnings and precautions Talk to your doctor, pharmacist or nurse before using Ilumetri:</p><ul><li>If you experience allergic reactions with symptoms such as chest tightness, wheezing, swelling of the face, lips or throat do not inject more Ilumetri and contact your doctor immediately.</li><li>If you currently have an infection or if you have long-term or repeated infections.</li><li>If you have recently had or plan to have a vaccination.</li></ul><p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Ilumetri.</p><p>Look out for infections and allergic reactions Ilumetri can potentially cause serious side effects, including infections and allergic reactions. You must look out for signs of these conditions while you are taking Ilumetri. Stop using Ilumetri and tell your doctor or seek medical help immediately if you notice any signs indicating a possible serious infection or an allergic reaction (see section 4. Possible side effects).</p><p>Children and adolescents Ilumetri is not recommended for use in children and adolescents under 18 years of age. This is because it has not yet been evaluated in this group of patients.</p><p>Other medicines and Ilumetri<br/>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. These include vaccines and immunosuppressants (medicines that affect the immune system).</p><p>You should not be given certain types of vaccines (live vaccines) while using Ilumetri. No data are available with the concomitant use of Ilumetri and live vaccines.</p><p>Pregnancy, breastfeeding and fertility It is preferable to avoid the use of Ilumetri in pregnancy. The effects of this medicine in pregnant women are not known.</p><p>If you are a woman of childbearing potential, you are advised to avoid becoming pregnant and must use an effective method of contraception whilst having treatment with Ilumetri and for at least 17 weeks after treatment.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>Driving and using machines Ilumetri has no or little effect on the ability to drive and use machines.</p></div>
</text>
</section>
<section>
<title value="3. How to take ilumetri"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take ilumetri"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Ilumetri is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of psoriasis.</p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. This medicine is for single use only.</p><p>The recommended dose of Ilumetri is 100 mg by subcutaneous injection at weeks 0, and 4 and every 12 weeks thereafter.<br/>If you are a patient with high disease burden or with a body weight above 90 kg, your doctor may decide that a dose of 200 mg is recommended for you.</p><p>Your doctor will decide for how long you need to take Ilumetri.</p><p>After proper training in subcutaneous injection technique, you may inject Ilumetri yourself if your doctor determines that it is appropriate.</p><p>For instructions on how to inject Ilumetri yourself, see Instructions for use at the end of this leaflet.</p><p>Talk to your doctor about when you will have your injections and follow-up appointments.</p><p>Use in children and adolescents The safety and efficacy of Ilumetri in children and adolescents under 18 years of age has not yet been established and therefore Ilumetri is not recommended for use in children or adolescents.</p><p>If you use more Ilumetri than you should If you have administered more Ilumetri than you should or the dose has been administered sooner than according to your doctor s prescription, tell your doctor.</p><p>If you forget to use Ilumetri If you have forgotten or missed an Ilumetri injection, administer the dose as soon as possible. Thereafter, resume dosing at the regularly scheduled interval.</p><p>If you stop using Ilumetri The decision to stop using Ilumetri should be discussed with your doctor. Your symptoms may return upon discontinuation.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects If you notice any of the following, contact your doctor immediately:</p><ul><li>Swelling of the face, lips or throat</li><li>Breathing difficulties As these may be signs of an allergic reaction.</li></ul><p>Other side effects Most of the following side effects are mild. If any of these side effects becomes severe, tell your doctor or pharmacist.</p><p>Very common (may affect more than 1 in 10 people)</p><ul><li>Upper respiratory infections</li></ul><p>Common (may affect up to 1 in 10 people)</p><ul><li>Gastroenteritis</li><li>Nausea</li><li>Diarrhoea</li><li>Injection site pain</li><li>Back pain</li><li>Headache</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store ilumetri"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store ilumetri"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the label of the pre-filled syringe after EXP. The expiry date refers to the last day of that month.</p><p>Keep the product in the original carton in order to protect from light. Do not shake.</p><p>Store in a refrigerator (2 C - 8 C). Do not freeze.</p><p>After taking a pre-filled syringe from the refrigerator, wait approximately 30 minutes to allow the Ilumetri solution in the syringe to reach room temperature (up to 25 C). Do not warm in any other way.</p><p>Do not use if the liquid contains visible particles, is cloudy or is distinctly brown.</p><p>Once taken out of the refrigerator, do not store tildrakizumab above 25 C or refrigerate it again. Write down the date of removal from the refrigerator in the space provided on the outer carton and appropriate discard date. Use the syringe within 30 days after taking it out of the refrigerator or by the expiry date whichever occurs first.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Ilumetri contains</p><ul><li>The active substance is tildrakizumab. Each pre-filled syringe contains 100 mg of tildrakizumab.</li><li>The other ingredients are L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose and water for injections.</li></ul><p>What Ilumetri looks like and contents of the pack<br/>Ilumetri 100 mg solution for injection (injection) in pre-filled syringe is a clear to slightly opalescent and colourless to slightly yellow solution. Ilumetri 100 mg solution for injection (injection) in pre-filled syringe is available in unit packs containing 1 pre-filled syringe and packs comprising 2 pre-filled syringes.<br/>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Almirall, S.A. Ronda General Mitre, 08022 Barcelona, Spain</p><p>Manufacturer SUN Pharmaceuticals Industries (Europe) B.V. Polarisavenue 2132JH Hoofddorp, Netherlands</p><p>Industrias Farmac uticas Almirall, S.A. Ctra. de Martorell 41-08740 Sant Andreu de la Barca, Barcelona, Spain</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien/ Luxembourg/Luxemburg<br/>Almirall N.V. T l/Tel: +32 (0)2 771 86 Italia<br/>Almirall SpA Tel: +39 02 346 / Eesti/ / Espa a/ Hrvatska/ / Latvija/ Lietuva/ Magyarorsz g/ Malta/ Rom nia/ Slovenija<br/>Almirall, S.A. Te ./Tel/ : +34 93 291 30 esk republika / Slovensk republika: Almirall s.r.o Tel: +420 739 686 Nederland<br/>Almirall B.V. Tel: +31 (0)307991Danmark/ Norge/ Sverige<br/>Almirall ApS Tlf/Tel: +45 70 25 75 sterreich<br/>Almirall GmbH Tel: +43 (0)1/595 39 Deutschland<br/>Almirall Hermal GmbH Tel: +49 (0)40 72704-0</p><p>Polska<br/>Almirall Sp.z o. o. Tel.: +48 22 330 02 France<br/>Almirall SAS, 1 T l: +33(0)1 46 46 19 Portugal<br/>Almirall - Produtos Farmac uticos, Lda.<br/>Tel: +351 21 415 57 Ireland/United Kingdom (Northern Ireland) Almirall, S.A. Tel: +353 (0) 1431 9Suomi/Finland Orion Pharma Puh/Tel: +358 10 4 sland<br/>Vistor hf. S mi: +354 535 70 This leaflet was last revised in</p><p>Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp4ef629a7127d0f0a54242fe28701c54c"/>
<resource>
<MedicinalProductDefinition>
<id value="mp4ef629a7127d0f0a54242fe28701c54c"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp4ef629a7127d0f0a54242fe28701c54c"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp4ef629a7127d0f0a54242fe28701c54c</b></p><a name="mp4ef629a7127d0f0a54242fe28701c54c"> </a><a name="hcmp4ef629a7127d0f0a54242fe28701c54c"> </a><a name="mp4ef629a7127d0f0a54242fe28701c54c-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/18/1323/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Ilumetri 100 mg solution for injection in pre-filled syringe</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/18/1323/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Ilumetri 100 mg solution for injection in pre-filled syringe"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
